株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:デュシェンヌ型筋ジストロフィー (DMD)

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

発行 Datamonitor Healthcare 商品コード 594577
出版日 ページ情報 英文 61 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
注目市場の分析:デュシェンヌ型筋ジストロフィー (DMD) Market Spotlight: Duchenne Muscular Dystrophy (DMD)
出版日: 2019年11月15日 ページ情報: 英文 61 Pages
概要

当レポートでは、デュシェンヌ型筋ジストロフィー (DMD) の治療薬市場について分析し、疾患の概要や患者数の推移・見通し、現段階での主な治療法、規制環境と近年の主な出来事、現在開発中の治験の進行状況と上市スケジュール、主な治療薬の市場動向見通し (今後10年間分)、資本取引の動きなどを調査しております。

分析のポイント

疾患の背景事情

治療法

  • コルチコステロイド
  • 遺伝子治療
  • ビタミンD補給

疫学

上市済み医薬品

  • 各国での認証状況

パイプライン上の医薬品

間もなく生じる主な出来事

規制関連の主な出来事 (計6件)

ライセンス契約・資産買収取引 (計4件)

母体特許

収益機会

治験情勢

  • スポンサー数:ステータス別
  • スポンサー数:フェーズ (相) 別
  • 近年の動向

関連分析

  • 処方薬の情報

付録

目次
Product Code: DMKC0181105

This Market Spotlight report covers the Duchenne Muscular Dystrophy market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, probability of success, recent events and analyst opinion, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were 182,100 prevalent cases of Duchenne muscular dystrophy (DMD) in males worldwide, and forecasts that number to increase to 199,100 prevalent cases by

2026. Marketed drugs for DMD include the FDA-approved drugs Emflaza, a glucocorticoid with anti-inflammatory and immunosuppressant properties, and Exondys 51, a novel phosphorodiamidate morpholino oligomer designed to induce the skipping of exon 51 in the dystrophin gene. The marketed drugs also include an EU-approved drug, Translarna, which acts by targeting premature nonsense mutations. Emflaza and Translarna are administered via the oral route, while Exondys 51 is available as an intravenous formulation.

The largest proportion of industry-sponsored drugs in active clinical development for DMD are in Phase II, with two drugs in the NDA/BLA phase.

Therapies in development for DMD focus on a wide variety of targets. The majority of pipeline drugs are administered via the intravenous or oral routes, with the remainder being intramuscular, intraarterial, and subcutaneous formulations.

High-impact upcoming events for drugs in the DMD space comprise topline Phase II and Phase III trial results, and an expected PDUFA date for an NDA.

The overall likelihood of approval of a Phase I single-gene disorders (non-inborn errors of metabolism) asset is 23.9%, and the average probability a drug advances from Phase III is 66.7%. Drugs, on average, take 7.2 years from Phase I to approval, compared to 8.8 years in the overall metabolic space.

There have been 21 licensing and asset acquisition deals involving DMD drugs during 2014-19, eight of which occurred in

2017. The largest deal during the period was the $3,520m licensing agreement between Vertex and CRISPR Therapeutics signed in 2017, as part of which the two companies will discover and develop gene editing therapies for the treatment of DMD and myotonic dystrophy type 1 (DM1).

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for DMD have been in the early and midphases of development, with 70% of trials in Phase I-II, and only 30% in Phase III-IV.

The US has a substantial lead in the number of DMD clinical trials globally. The UK leads the major EU markets, while Israel has the top spot in Asia.

Sarepta Therapeutics has the highest number of ongoing trials for DMD, with nine trials.

PTC Therapeutics leads industry sponsors with the highest number of clinical trials for DMD, followed by Sarepta Therapeutics.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Corticosteroids
  • Genetic therapies
  • Vitamin D supplement

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Golodirsen for DMD (August 19, 2019)
  • CAP-1002 for DMD (July 15, 2019)
  • PF-06939926 for DMD (June 28, 2019)
  • SingleCut CRISPR-Cas9 Program (Exonics) for DMD (June 6, 2019)
  • AT702 for DMD (April 8, 2019)
  • Casimersen for DMD (March 28, 2019)
  • Catena for DMD (February 25, 2019)
  • SGT-001 for DMD (February 7, 2019)
  • Emflaza for DMD (January 7, 2019)
  • CAP-1002 for DMD (December 21, 2018)
  • PF-06252616 for DMD (August 30, 2018)
  • Multiple Drugs for DMD (August 30, 2018)
  • Ezutromid for DMD (June 27, 2018)
  • Viltolarsen for DMD (June 27, 2018)
  • SRP-9001 for DMD (June 19, 2018)
  • SGT-001 for DMD (June 18, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Sarepta's Vyondys 53 Whiff Looks Costly As Nippon Shinyaku Submits Viltolarsen
  • Sarepta Surprised By CRL For Exon 53-Skipping DMD Drug Golodirsen
  • PTC To Fight EMA Translarna No

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Vertex Gene-Editing Play Includes Exonics Buy, Expanded Tie-Up With CRISPR
  • Audentes Gains License To NCH's DMD, DM1 Candidates
  • Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of DMD, 2017-26
  • Figure 2: Overview of pipeline drugs for DMD in the US
  • Figure 3: Pipeline drugs for DMD, by company
  • Figure 4: Pipeline drugs for DMD, by drug type
  • Figure 5: Pipeline drugs for DMD, by classification
  • Figure 6: CAP-1002 for DMD (July 15, 2019): Phase II - HOPE-2
  • Figure 7: Casimersen for DMD (March 28, 2019): Phase III - ESSENCE (Study 4045-301; Exon 45 & 53)
  • Figure 8: Catena for DMD (February 25, 2019): Phase III - SYROS
  • Figure 9: PF-06252616 for DMD (August 30, 2018): Phase II - PK and PD Study
  • Figure 10: Ezutromid for DMD (June 27, 2018): Phase II - PhaseOut DMD (US and EU)
  • Figure 11: Viltolarsen for DMD (June 27, 2018): Phase II - 201
  • Figure 12: SRP-9001 for DMD (June 19, 2018): Phase I/IIa - pilot study
  • Figure 13: Key upcoming events in DMD
  • Figure 14: Probability of success in the DMD pipeline
  • Figure 15: Licensing and asset acquisition deals in DMD, 2014-19
  • Figure 16: Parent patents in DMD
  • Figure 17: Clinical trials in DMD
  • Figure 18: Top 10 drugs for clinical trials in DMD
  • Figure 19: Top 10 companies for clinical trials in DMD
  • Figure 20: Trial locations in DMD
  • Figure 21: DMD trials status
  • Figure 22: DMD trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of DMD, 2017-26
  • Table 2: Marketed drugs for DMD
  • Table 3: Pipeline drugs for DMD in the US
  • Table 4: Golodirsen for DMD (August 19, 2019)
  • Table 5: CAP-1002 for DMD (July 15, 2019)
  • Table 6: PF-06939926 for DMD (June 28, 2019)
  • Table 7: SingleCut CRISPR-Cas9 Program (Exonics) for DMD (June 6, 2019)
  • Table 8: AT702 for DMD (April 8, 2019)
  • Table 9: Casimersen for DMD (March 28, 2019)
  • Table 10: Catena for DMD (February 25, 2019)
  • Table 11: SGT-001 for DMD (February 7, 2019)
  • Table 12: Emflaza for DMD (January 7, 2019)
  • Table 13: CAP-1002 for DMD (December 21, 2018)
  • Table 14: PF-06252616 for DMD (August 30, 2018)
  • Table 15: Multiple Drugs for DMD (August 30, 2018)
  • Table 16: Ezutromid for DMD (June 27, 2018)
  • Table 17: Viltolarsen for DMD (June 27, 2018)
  • Table 18: SRP-9001 for DMD (June 19, 2018)
  • Table 19: SGT-001 for DMD (June 18, 2018)
  • Table 20: Historical global sales, by drug ($m), 2014-18
  • Table 21: Forecasted global sales, by drug ($m), 2019-23
Back to Top